Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 10, 2009, Pages 1377-1386

  Pohl, Michael ^a   Stricker, I ^b   Schoeneck, A ^a   Schulmann, K ^a   Klein Scory, S ^a   Schwarte Waldhoff, I ^a   Hasmann, M ^c   Tannapfel, A ^b   Schmiegel, W ^a,b   Reinacher Schick, A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Colorectal cancer; Dual ErbB inhibition; HER dimerization inhibitor; Irinotecan; Pertuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; IRINOTECAN; PERTUZUMAB;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL CYCLE PROGRESSION; CELL STRAIN HCT116; CELLULAR DISTRIBUTION; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MONOTHERAPY; MOUSE; NECROSIS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DIMERIZATION; DRUG THERAPY, COMBINATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MICE; MICE, NUDE; PROTEIN MULTIMERIZATION; QUINAZOLINES; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69049112804     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0579-3     Document Type: Article

References (44)

1. CW Adams DE Allison K Flagella, et al. 2006 Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab Cancer Immunol Immunother 55 717 727 10.1007/s00262-005-0058-x
2. DB Agus RW Akita WD Fox GD Lewis 2002 Targeting ligand-activated ErbB-2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 127 137 10.1016/S1535-6108(02)00097-1
3. DB Agus MS Gordon C Taylor, et al. 2005 Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer J Clin Oncol 23 2534 2542 10.1200/JCO.2005.03.184
4. RW Akita MX Sliwkowski 2003 Preclinical studies with erlotinib (Tarceva) Semin Oncol 30 15 24
5. G Arpino C Gutierrez H Weiss, et al. 2007 Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy J Natl Cancer Inst 99 694 705 10.1093/jnci/djk151
6. J Baselga CL Arteaga 2005 Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2445 2459 10.1200/JCO.2005.11.890
7. JD Black MG Brattain SA Krishnamurthi DM Dawson JK Willson 2003 ErbB family targeting Curr Opin Investig Drugs 4 1451 1454
8. G Carpenter S Cohen 1990 Epidermal growth factor J Biol Chem 265 7709 7712
9. MA Cobleigh CL Vogel D Tripathy, et al. 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648
10. A Dursun A Poyraz O Suer C Sezer G Akyol 2001 Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia Pathol Oncol Res 7 24 27
11. Ferlay J, Bray F, Pisani P et al (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC cancerbase no. 5. IARC, Lyon, France
12. LA Fields D Rinaldi CA Henderson, et al. 2005 An open-label multicenter phase II study of oral Lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer J Clin Oncol 23 3583
13. MC Franklin KD Carey FF Vajdos DJ Leahy AM deVos MX Sliwkowski 2004 Insights into ErbB signaling from the structure of the ErbB-2-pertuzumab complex Cancer Cell 5 317 328 10.1016/S1535-6108(04)00083-2
14. T Friess S Bauer AM Burger 2002 In vivo activity of recombinant humanized monoclonal antibody 2C4 in xenografts is independent of tumor type and degree of HER-2 overexpression Eur J Cancer 38 149 156
15. T Friess W Scheuer M Hasmann 2005 Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy Clin Cancer Res 11 5300 5309 10.1158/1078-0432.CCR-04-2642
16. V Grunwald M Hidalgo 2003 Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774) Adv Exp Med Biol 532 235 246
17. AW Hemming NL Davis A Kluftinger, et al. 1992 Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki-67 J Surg Oncol 51 147 152 10.1002/jso.2930510304
18. YP Hu S Venkateswarlu N Sergina, et al. 2005 Reorganization of ErbB family and cell survival signalling following knockdown of ErbB-2 in colon cancer cells J Biol Chem 280 27383 27392 10.1074/jbc.M414238200
19. JG Jackson P St. Clair MX Sliwkowski MG Brattain 2004 Blockage of epidermal growth factor- or heregulin-dependent ErbB-2 activation with the anti-ErbB-2 monoclonal antibody 2C4 has divergent downstream signalling and growth effects Cancer Res 64 2601 2609 10.1158/0008-5472.CAN-03-3106
20. JR Johnson M Cohen R Sridhara, et al. 2005 Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen Clin Cancer Res 11 6414 6421 10.1158/1078-0432.CCR-05-0790
21. S Kapitanovic R Spaventi L Poljak, et al. 1994 High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters Cancer Detect Prev 18 97 101
22. S Kapitanovic S Radosevic M Kapitanovic, et al. 1997 The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer Gastroenterology 112 1103 1113 10.1016/S0016-5085(97)70120-3
23. SK Kuwada CL Scaife J Kuang, et al. 2004 Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells Int J Cancer 109 291 301 10.1002/ijc.11686
24. PA Learn N Krishnegowda J Talamantez MS Kahlenberg 2006 Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines J Surg Res 136 227 231 10.1016/j.jss.2006.07.046
25. M Mann H Sheng J Shao, et al. 2001 Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth Gastroenterology 120 1713 1719 10.1053/gast.2001.24844
26. A Mayer M Takimoto E Fritz, et al. 1993 The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer Cancer 71 2454 2460 10.1002/1097- 0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2
27. J Mendelsohn 2002 Targeting the epidermal growth factor receptor for cancer therapy J Clin Oncol 20 1S 13S
28. JA Meyerhardt AX Zhu PC Enzinger, et al. 2006 Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer J Clin Oncol 24 1892 1897 10.1200/JCO.2005.05.3728
29. MJ Moore D Goldstein J Hamm, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 10.1200/JCO.2006.07.9525
30. N Normanno C Bianco A De Luca, et al. 2003 Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment Endocr Relat Cancer 10 1 21 10.1677/erc.0.0100001
31. R Pérez-Soler A Chachoua LA Hammond, et al. 2004 Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 3238 3247 10.1200/JCO.2004.11.057
32. VA Pollack DM Savage DA Baker, et al. 1999 Inhibition of epidermal growth factor receptorassociated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice J Pharmacol Exp Ther 291 739 748
33. I Porebska A Harlozinska T Bojarowski 2000 Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas Tumour Biol 21 105 115 10.1159/000030116
34. MC Prewett AT Hooper R Bassi, et al. 2002 Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts Clin Cancer Res 8 994 1003
35. RK Ramanathan JJ Hwang WC Zamboni, et al. 2004 Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial Cancer Invest 22 858 865 10.1081/CNV-200039645
36. FX Real WJ Rettig PG Chesa, et al. 1986 Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation Cancer Res 46 4726 4731
37. JS Ross BJ McKenna 2001 The HER-2/neu oncogene in tumors of the gastrointestinal tract Cancer Invest 19 554 568 10.1081/CNV-100103852
38. N Saijo 2000 Preclinical and clinical trials of topoisomerase inhibitors Ann NY Acad Sci 922 92 99
39. DS Salomon R Brandt F Ciardiello, et al. 1995 Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183 232 10.1016/1040-8428(94)00144-I
40. L Saltz MS Rubin HS Hochster 2001 Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Proc Am Soc Clin Oncol 20 7 Abstract
41. LB Saltz NJ Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 1201 1208 10.1200/JCO.2004.10.182
42. N Takai J Anjali K Norihiko, et al. 2005 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth Cancer 104 2701 2708 10.1002/cncr.21533
43. CA Townsley P Major LL Siu, et al. 2006 Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer Br J Cancer 94 1136 1143 10.1038/sj.bjc.6603055
44. Y Zhou S Li YP Hu, et al. 2006 Blockade of EGFR and ErbB-2 by the novel dual EGFR and ErbB-2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis Cancer Res 66 404 411 10.1158/0008-5472.CAN-05- 2506